Drug Trial Radar · NCT01953926
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
582
Actual
Start
Sep 30, 2013
Primary completion
Jan 2, 2023
Study completion Jan 2, 2023
Sponsor
- Lead sponsor
- Puma Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Interventions
NeratinibDrug
240 mg administered orally, once daily with food, continuously in 28 day cycles
FulvestrantDrug
500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
TrastuzumabDrug
Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
PaclitaxelDrug
80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) by Independent Central Review (Breast Cancer With Prior CDK46i Cohort)Time frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 58 months
- Confirmed Objective Response Rate (ORR) by Investigator Review (Cervical Cancer Cohort)Time frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 58 months
- Objective Response Rate (ORR) at First Assessment by Investigator Review (All Other Cohorts)Time frame: From first treatment date to first Complete or Partial Response, whichever came earlier, assessed up to 8 or 9 weeks
Locations
60 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Arizona
Phoenix, Arizona
City of Hope
Duarte, California
University of California, San Diego
La Jolla, California
University of Southern California
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Kaiser Permanente NoCal (STRATA)
Vallejo, California
Mayo Clinic Florida
Jacksonville, Florida
University of Miami
Miami, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota
Washington University
St Louis, Missouri
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
UPMC Magee-Woman's Hospital, Women's Cancer Center
Pittsburgh, Pennsylvania
Saint Francis Cancer Center-Bon Secours
Greenville, South Carolina
The West Clinic
Germantown, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Gundersen Center for Cancer and Blood Disorders
La Crosse, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia
UZ Leuven
Leuven, Belgium
British Columbia Cancer Center
Vancouver, British Columbia, Canada
University Hospital, Rigshospitalet
Copenhagen, Denmark
Institut Bergonié
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Curie - Hopital Rene Huguenin
Saint-Cloud, Île-de-France Region, France
Institut Gustave Roussy
Villejuif, Paris, France
St. Vincent's University Hospital
Dublin, Leinster, Ireland
Hadassah Medical Center
Jerusalem, Israel
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.